ESRRA and breast cancer: Table 1 contains some potential approaches that could indirectly halt PCG-1α-associated metabolic reprogramming by targeting PPARa or ERRα. Lastly, a recent study showed that inhibiting ERRα exposes a metabolic vulnerability in breast cancer cells and increases the efficacy of glycolysis or glutaminolysis inhibitors [78].